Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
MarketBeatJohnson & Johnson’s Q1 2024 earnings offer a mixed picture of resilience amidst economic headwinds and provide insight into the broader medtech sector’s health.
Johnson & Johnson’s Q1 2024 earnings offer a mixed picture of resilience amidst economic headwinds and provide insight into the broader medtech sector’s health.